Skip to main content

FDA Alerts

The FDA has recently approved a new once-daily topical treatment for adult patients with plaque psoriasis.
The FDA approved guselkumab, a selective IL-23 inhibitor, for the treatment of adult patients with active psoriatic arthritis.
The FDA has approved a new topical foam medication for the treatment of inflammatory lesions caused by rosacea in adults.
The FDA approved a new therapy to increase pain-free light exposure in adult patients with a history of phototoxic reactions caused by erythropoietic protoporphyria.
The FDA recently approved a new topical retinoid for the treatment of acne on both the face and the trunk.
The FDA approved the expanded indication of topical dapsone 7.5% gel for the treatment of acne vulgaris in patients aged 9 to 11 years.
The FDA approved a new treatment option for patients with oral ulcers associated with Behçet disease.
The FDA has approved the first treatment option for chronic, inadequately controlled rhinosinusitis with nasal polyps.
The FDA approved a new foam treatment for adolescents with plaque psoriasis on the scalp and body.
The FDA has approved a second biosimilar to etanercept for the treatment of various autoimmune conditions.

Back to Top